Acccording to Novo Nordisk, the Wegovy pill can deliver a level of weight loss unmatched by any other oral GLP-1 obesity candidate in phase 3 trials, achieving an average weight loss of approximately 17% (16.6%) when used alongside a reduced-calorie diet and exercise and when all patients remained on treatment, compared with about 3% (2.7%) for placebo
Prescriptions, particularly for controlled substances, may require an in-person evaluation depending on the state of residence and current federal regulations
Treatment with oral semaglutide resulted in a mean A1C reduction from baseline of -1.3% at week 52 for both estimand calculations
We observed an initial blunted response at time points 10 ( BrAC Control = 0.037, BrAC GLP-1RA = 0.021, t(113) = 3.21, p = 0.014), 15 ( BrAC Control = 0.028, BrAC GLP-1RA = 0.013, t(113) = 2.98, p = 0.028) and 20 min (BrAC Control = 0.037, BrAC GLP-1RA = 0.017, t(113) = 3.87, p = 0.001) in the GLP-1RA group as compared to the control group
Prioritise bioavailability: Use liposomal or liquid forms that bypass digestive degradation